Novartis and Johnson & Johnson to deprive Europeans of their right to Health

Novartis-Logo (1)

It was the last day of January that the European Commission decided to send a formal complaint against two pharmaceutical giants, Johnson and Johnson and Novartis, over an illegal secret deal that made European cancer patients suffer while it brought huge profits to the American and Swiss multinational accordingly.

After the meticulous research of DG Competition, that as usually, took around 10 years to bear fruit, it has been uncovered that the two of the three biggest Pharmaceutical companies of the world according to Forbes, were having a small party in Netherlands between 2005 and 2006 at the expense of the Dutch cancer patient. According to DG Comp, what was happening back then is that the Dutch branch of Johnson & Johnson in the Netherlands, Janssen-Cilag, had in its payroll for one year and a half a competitive pharmaceutical company specialized in generics called Sandoz. The latter is a proper known unit of the Swiss company Novartis. So, basically, Johnson and Johnson were paying to Novartis a huge amount of money for 17 months. Isn’t that weird? Competitor companies are supposed to have endless board meetings on how to steal money from each other and not sharing bribes. Was 2005 the year that the management of the two powerful companies lost their minds due to burnout?

The Pay for Delay Deal

Well, think again! These people knew very well what they were doing. We are talking here about the anticompetitive bad practice of Pharmaceuticals called “Pay for Delay” where one brand name is bribing the generic drug competitor in order to delay the release of the cheaper generic drug in the market. In our case the generic drug that was deliberately and illegally delayed to launch in the Dutch market is Fentanyl and it is a drug that is mainly used by cancer patients to relieve pain. In a nutshell, these two companies deprived the Dutch cancer patients from the right to be able to buy a much cheaper drug, so that they can save millions of Euros by preventing a market share loss that a cheaper substitute product in the market would bring.

On the antitrust statement of DG Competition on the 31st of January, Mr. Almunia, the EU Competition Commissioner, said: “If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called “co-promotion” agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper pain killer,”… “The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care”. The Basque EU Commissioner says it here very well, but he certainly cannot say anything to the Dutch patients that were not given the alternative of cheap Fentanyl for 17 monhts! Can he?

DG Comp is doing Fundraising

Unfortunately, it seems that this antitrust statement can serve only in two things: a) make impression and b) make the Commission richer. If the Commission wins this battle with the pharmaceutical dinosaurs, which we all hope it will, the only benefit will be a few billion Euros for DG Comp. And of course we live in crisis and Mr. Almunia needs to play the role of the Fundraiser but in the end of the day this will not solve the Pay for Delay syndrome that is expanding like a plague in Europe and is menacing significantly public health. I mean, what is 7 billion euros for Johnson and Johnson to pay as fine compared to the millions or billions that the company has probably saved by exercising this anticompetitive covert technique? And of course, we are talking here about one case that goes back 10 years ago and was uncovered now. Who knows how many other similar incidents we had or we have at this moment in Europe happening at the expense of the European citizen, which will never see the light of publicity? Hence, the culminant question here is: What next? How can the European citizen be sure that this kind of corporate bribing will not be repeated in the future?

The European Parliament had an idea

Only a week after the antitrust statement, a new draft law was voted on the 6th of February in the European Parliament that seems relevant to the topic of this story. The basic concept behind that is that European patients should be able to buy cheaper generic medicines. This is an excellent concept. The European Sting and all Europeans welcome this spirit from the European law makers without a doubt. However, the European Parliament only voted in favour of some new deadlines and transparency standards on pricing and reimbursement of generic medicines. As usually, all this will be addressed to the 27 member states.

Of course, this is something that Europe needed to have anyway, because the rules that are now in action and describe these procedures are almost 25 years old (1989). It is true that the procedures were poorly defined and slow while, as Mrs. Antoniya Parvanova, rapporteur from the Alliance of Liberals and Democrats for Europe (ALDE), said, sometimes it took a country up to 700 days to make decisions on pricing and reimbursement of medicines. However, why was this matter brought up in the European Parliament now and not before? Is it to take the next step after Mr. Almunia’s antitrust statement?

I am afraid not. The reasons are twofold:

a)      This vote apparently is not going to stop Pharmaceuticals to pay for delay

b)      The draft law was voted on the 6th of February, when on the 4th was the World Cancer Day. The period that the draft law was voted was a period with numerous events aiming at cancer awareness all around the world. Is it a coincidence that the flash addicted European Parliament voted for this in the beginning of February and not in March?

Overall the draft law is a good reform addressed to member states to improve the European health system as a whole but let’s be honest here. Big Pharmaceuticals will be still free out there to sign golden deals under the table with generic competitors, in order to delay the launch of their product so that they keep the prices and profits high for themselves. Who will touch these people? Or better who can touch these people? Is a few billion fine enough to make them stop?

I guess not. The only cure from this cancer is that the patient, the European citizen, is aware of what exactly is happening behind her back and I hope that with this story the Sting has contributed to that.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Can self-charging batteries keep us connected for ever? A young scientist explains

EU attempts to make new deal with Turkey as relations deteriorate

5G and the growing need for national CTOs

UN Middle East Coordinator strongly condemns ‘arrests and violence’ by Hamas security forces during Gaza protests

Colombia: Santos thanks the EU for its support to the peace process

Digital IDs and the Digital Economy: the (still) missing link?

These artists created a huge open library – and their idea’s gone global

Bayer’s cross at night (Copyright: Bayer AG)

The EU clears Bayer-Monsanto merger amid wide competition and environmental concerns

EU budget agreement rejected by the European Parliament

IMF: Sorry Greece, Ireland, Portugal we were wrong!

Guinea-Bissau needs ‘genuinely free and fair elections’ to break cycle of instability

‘No safe way’ into battle-scarred Afghan city of Ghazni to deliver aid as traumatized children search for parents

Gender parity has a huge role to play in the fight to save our oceans

First EU-wide protection for whistle-blowers agreed

Europe should make voice ‘more heard’ in today’s ‘dangerous world,’ says UN chief

FROM THE FIELD: ‘A piece of me’ was taken

Engaging women and girls in science ‘vital’ for Sustainable Development Goals

A new approach to scaling-up renewable power in emerging markets

This billion-dollar campaign wants to protect 30% of the planet by 2030

3 ways to make the 2020s the decade we close the gender gap

Coronavirus: a cultural escape goat or the next Big Five

MEPs approve boost to workers’ rights in the gig economy

Commission offers discount on fines to banks for competition infringements

UK voters sent strong message to May and Corbyn for soft Brexit

Norway initiates WTO dispute complaint against US steel, aluminium duties

Stage set for successful 2020 Burundi elections, Foreign Minister tells General Assembly

Eurozone: Economic sentiment-business climate to collapse without support from exports

Service and sacrifice of African peacekeepers ‘at the forefront of our minds’: UN chief

A new catastrophic phase in the Syrian carnage

Algorithms are being used to convict criminals and decide jail time. We need to make sure they are fair

Humanitarian aid: EU announces additional €35 million for Africa’s Sahel region

The reskilling revolution can transform the future of work for women

A Sting Exclusive: Healthy oceans amidst COVID-19, written by the United Nations Under-Secretary General

It’s time to end our ‘separate but unequal’ approach to mental health

Citizens to be the cornerstone of the Conference on the Future of Europe

GSMA Outlines New Developments For MWC19 Shanghai

Commission caps charges on card and Internet payments and enforces competition

UN chief applauds Bangladesh for ‘opening borders’ to Rohingya refugees in need

EU Trade Ministers come together in a desperate attempt to save TTIP

A win-win strategy for private equity deals

The Cold War had an unintended side effect: It created a European wildlife paradise

Immigration crisis at its very worst: EU to outsource rescue business to North Africa?

Security Union: Commission receives mandate to start negotiating international rules for obtaining electronic evidence

Walk, cycle, dance and play – UN health agency recommends new action plan for good health

Impact Investment needs global standards and better measurement

What can we do about the crisis in trust in public institutions?

Tokyo Olympics postponed to 2021 over coronavirus concerns

Mental Health x Meditation, in times of pandemic: cognitive and behavioral modifications

Indonesian tsunami death toll climbs over 400 as Government-led relief efforts are stepped up

5 ways to integrate Syrian refugees into the workforce

Technology companies have power. They must assume responsibility

EU Youth Conference in Riga concludes with recommendations for ministers

Human rights are everyone’s business, amid relentless crises around world: UN’s Bachelet

Here are 4 of the most politically charged World Cup games ever played

5G in Russia: a local and global view on the way forward, in association with The European Sting

The world wide web is 30 years old. What better time to fight for its future?

On International Youth Day the European Youth Forum calls for true youth participation

The growing cyber-risk to our electricity grids – and what to do about it

Why lay people don’t expect anything good from G20

The world’s most vulnerable must be protected: WHO briefing

More Stings?

Advertising

Comments

  1. I believe this is one of the so much important information for me.
    And i’m satisfied studying your article. But wanna
    remark on few basic things, The site style is perfect, the articles is in point of fact excellent : D.
    Just right task, cheers

Leave a Reply to Corinne Cancel reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s